Magnus Unemo on Zoliflodacin treatment for gonorrhea
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
Elisa Pucu from The Lancet Microbe interviews Dr. Magnus Unemo of Örebro University about the clinical implications and key findings from his research. They discuss about the the microbiological analysis and whole genome sequencing of treatment failures from the zoliflodacin phase 3 clinical trial for gonorrhea—revealing insights that could change the future of treatment and antibiotic resistance.
Click here to read the full articles: https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00198-3/fulltext
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01953-1/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv